Table 2. CTL Activity and Cell Phenotype... | American Society of Hematology

Table 2.

CTL Activity and Cell Phenotype After IVS

Patient No.	Activity	LU20/10⁶ Cells		Cell Subsets	%CD8⁺ Lymphocytes
		Condition	vCP300 + IL7		Condition	OKT3	vCP300 + IL7
		OKT3			PBL
4	Anti-Env	4	5	CD3⁺CD8⁺	55	79	72
	Anti-Gag	6	27	CD8⁺CD45RA⁺	33	41	40
	Anti-Pol	17	59	CD8⁺CD45RO⁺	25	33	29
	Anti-Nef	17	68	CD8⁺HLA-DR⁺	32	29	32
				CD8⁺CD25⁺	1	33	14
				CD8⁺CD38⁺	27	79	61
				CD3⁻CD56⁺16⁺	7	13	20
8	Anti-Env	13	16	CD3⁺CD8⁺	34	84	82
	Anti-Gag	18	47	CD8⁺CD45RA⁺	24	52	39
	Anti-Pol	23	64	CD8⁺CD45RO⁺	15	42	38
	Anti-Nef	21	62	CD8⁺HLA-DR⁺	16	38	52
				CD8⁺CD25⁺	1	22	5
				CD8⁺CD38⁺	9	77	55
				CD3⁻CD56⁺16⁺	10	7	7
9	Anti-Env	8	60	CD3⁺CD8⁺	31	83	78
	Anti-Gag	2	48	CD8⁺CD45RA⁺	13	69	44
	Anti-Pol	7	22	CD8⁺CD45RO⁺	15	34	48
	Anti-Nef	5	46	CD8⁺HLA-DR⁺	18	28	73
				CD8⁺CD25⁺	1	9	10
				CD8⁺CD38⁺	9	83	64
				CD3⁻CD56⁺16⁺	17	7	5
10	Anti-Env	6	20	CD3⁺CD8⁺	40	71	64
	Anti-Gag	7	28	CD8⁺CD45RA⁺	31	37	10
	Anti-Pol	1	94	CD8⁺CD45RO⁺	11	15	30
	Anti-Nef	33	68	CD8⁺HLA-DR⁺	24	41	34
				CD8⁺CD25⁺	1	5	13
				CD8⁺CD38⁺	19	46	42
				CD3⁻CD56⁺16⁺	3	11	24

Patient No.	Activity	LU20/10⁶ Cells		Cell Subsets	%CD8⁺ Lymphocytes
		Condition	vCP300 + IL7		Condition	OKT3	vCP300 + IL7
		OKT3			PBL
4	Anti-Env	4	5	CD3⁺CD8⁺	55	79	72
	Anti-Gag	6	27	CD8⁺CD45RA⁺	33	41	40
	Anti-Pol	17	59	CD8⁺CD45RO⁺	25	33	29
	Anti-Nef	17	68	CD8⁺HLA-DR⁺	32	29	32
				CD8⁺CD25⁺	1	33	14
				CD8⁺CD38⁺	27	79	61
				CD3⁻CD56⁺16⁺	7	13	20
8	Anti-Env	13	16	CD3⁺CD8⁺	34	84	82
	Anti-Gag	18	47	CD8⁺CD45RA⁺	24	52	39
	Anti-Pol	23	64	CD8⁺CD45RO⁺	15	42	38
	Anti-Nef	21	62	CD8⁺HLA-DR⁺	16	38	52
				CD8⁺CD25⁺	1	22	5
				CD8⁺CD38⁺	9	77	55
				CD3⁻CD56⁺16⁺	10	7	7
9	Anti-Env	8	60	CD3⁺CD8⁺	31	83	78
	Anti-Gag	2	48	CD8⁺CD45RA⁺	13	69	44
	Anti-Pol	7	22	CD8⁺CD45RO⁺	15	34	48
	Anti-Nef	5	46	CD8⁺HLA-DR⁺	18	28	73
				CD8⁺CD25⁺	1	9	10
				CD8⁺CD38⁺	9	83	64
				CD3⁻CD56⁺16⁺	17	7	5
10	Anti-Env	6	20	CD3⁺CD8⁺	40	71	64
	Anti-Gag	7	28	CD8⁺CD45RA⁺	31	37	10
	Anti-Pol	1	94	CD8⁺CD45RO⁺	11	15	30
	Anti-Nef	33	68	CD8⁺HLA-DR⁺	24	41	34
				CD8⁺CD25⁺	1	5	13
				CD8⁺CD38⁺	19	46	42
				CD3⁻CD56⁺16⁺	3	11	24

Anti-HIV reactivities are reported as LU₂₀ /10⁶ cells, subtracting the anti-vaccinia background.